An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595
Sponsor: Inmune Bio, Inc.
Terminated
Sponsor resource allocation
Other terminated trials from Inmune Bio, Inc.
More terminations from Inmune Bio, Inc.
Other Alzheimer Disease trials with similar outcome
Listed as NCT05522387, this PHASE2 trial focuses on Alzheimer Disease and Brain Diseases and remains terminated or withdrawn. Sponsored by Inmune Bio, Inc., it has been updated 6 times since 2023, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Jun 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Inmune Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .